A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Completed · Phase 2 · Has a placebo group

Conditions studied: Hyperlipidemia, Type 2 Diabetes

In brief

This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.

Key facts

Study ID

NCT01607294

Run by

Esperion Therapeutics, Inc.

People needed

60

Starts

2012-04-01

Expected to finish

2012-10-01

Last updated by the study team

2019-03-29

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of type 2 diabetes meeting all of the following:
• Minimum 6 month history of diabetes prior to screening visit;
• Fasting C-peptide ≥ 0.8 ng/mL at screening visit;
• HbA1C at screening visit 7-10%;
• Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose regulating drugs and supplements.
• BMI at screening visit from 25-35 kg/m2;
• LDL-C at screening ≥ 100 mg/dL

Where it is running

• Study site — Miramar, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.